论文部分内容阅读
目的通过联合检测小细胞肺癌患者化疗前后血清血小板源性生长因子-BB(PDGF-BB)、D-二聚体(D-D)、神经元特异性烯化酶(NSE)的含量变化,为小细胞肺癌病情的评估提供新思路。方法应用电化学发光法、ELISA等方法对46例小细胞肺癌患者进行了治疗前后血清PDGF-BB、D-D、NSE联合检测含量水平的检测,并与65例正常健康者作比较。结果小细胞肺癌患者在化疗前血清PDGF-BB、D-D、NSE联合检测含量水平均显著高于对照组(P<0.01),经化疗治疗6个月内未复发的32例中明显下降接近于正常人,与对照组比较差异无统计学意义(P>0.05);而在6个月复发的14例患者中其数值又回升至治疗前水平(P<0.05)。结论血清PDGF-BB、D-D、NSE联合检测含量变化与患者的病情和预后密切相关,可作为诊断和疗效观察的重要参考依据。
Objective To detect the changes of serum platelet-derived growth factor-BB (PDGF-BB), D-dimer (DD) and neuron specific enolase (NSE) before and after chemotherapy in patients with small cell lung cancer Evaluation of lung cancer provides new ideas. Methods The levels of serum PDGF-BB, D-D and NSE in 46 patients with small cell lung cancer before and after treatment were detected by electrochemiluminescence and ELISA, and compared with 65 healthy controls. Results The levels of PDGF-BB, DD, NSE in patients with SCLC before chemotherapy were significantly higher than those in the control group (P <0.01), and those in 32 patients who did not relapse within 6 months after chemotherapy were close to normal There was no significant difference between the control group and the control group (P> 0.05). However, the values returned to the pre-treatment levels in 14 patients with recurrence at 6 months (P <0.05). Conclusions The changes of serum PDGF-BB, D-D and NSE levels are closely related to the patient’s condition and prognosis, which can be used as an important reference for the diagnosis and curative effect observation.